OpenAI 收购 Orchestra Bio，打造加速药物研发的 AI 智能体
原标题：OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
AI 摘要
OpenAI 收购了帮助药企团队协调药物研发的初创公司 Orchestra Bio，并将其并入面向生命科学的 AI 平台 Rosalind。合并后的团队将构建 AI 智能体，把科学发现与临床试验、决策和后续步骤连接起来，以加快新药上市。Orchestra 的智能体可跟踪试验、在出现生产批次失败等问题时标记受影响的时间线，并给出后续选项。OpenAI 此前已与诺和诺德、Moderna 合作开展 AI 药物研究，交易财务条款未披露。
正文节选
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development OpenAI is making a bigger bet on pharmaceuticals. The company acquired Orchestra Bio, a startup that helps pharma teams coordinate drug development. Orchestra will be folded into Rosalind, OpenAI's AI platform for life sciences. GPT-Rosalind helps researchers analyze biological and chemical questions, while Rosalind Workbench connects those capabilities with scientific data and tools. The combined effort aims to buil